News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Immunotherapy with chemo improves survival for aggressive relapsed lymphoma
Joshua Brody/X
Aug 9, 2024, 10:21

Immunotherapy with chemo improves survival for aggressive relapsed lymphoma

Joshua Brody, Director of the Lymphoma Immunotherapy Program at the Icahn School of Medicine at Mount Sinai, shared on LinkedIn:

“In relapsed aggressive lymphoma, adding bispecific CD3xCD20 immunotherapy to chemo DOUBLES Overall Survival and Complete Remissions! To 59%!

STARGLO trial treating patients at ~70 hospitals around the world including Mount Sinai.”

Read further.
Source: Joshua Brody/LinkedIn

 

cancer Icahn School of Medicine at Mount Sinai immunotherapy Joshua Brody lymphoma OncoDaily Oncology Starglo
Special Coverage
Blog
Mar 31, 2025, 14:02
Highlights from NCCN2025
Blog
Mar 31, 2025, 13:50
Raymond Chan: More MRFF funding for Flinders University on dementia and cancer survivorship
Blog
Mar 31, 2025, 13:37
Arun Shahi: Honored to be a guest of honor at the Maximizing Life Gala 2025
Blog
Mar 31, 2025, 13:24
Donal McLornan: Practical online tool to aid the transplant decision and discussion
Oncolibrary
Mar 31, 2025, 13:15
FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer
Insight
Mar 31, 2025, 13:03
Jennifer Lovick: Latest research from Technology in Cancer Research and Treatment's March round-up
Blog
Mar 31, 2025, 12:35
Zainul Aabideen: Spreading knowledge to save children with cancer
Blog
Mar 31, 2025, 12:34
MD Anderson Cancer Center - Physicians Share What They Love About Their Work for National Doctors' Day
Science
Mar 31, 2025, 12:30
Myeloma Paper of the Day, March 31st, suggested by Robert Orlowski
Blog
Mar 31, 2025, 12:28
Wafaa Rashed: Empowering the Next Generation of Genetics Policy Advocates
Oncolibrary
Mar 31, 2025, 12:26
New Paper Alert: Low-dose CT for lung cancer screening in a high-risk population (SUMMIT study)
Blog
Mar 31, 2025, 12:26
Drew Moghanaki: Selective SBRT can help patients with metastatic EGFR+ NSCLC get more MILEAGE out of every one of these drugs